HUMAN MICROBIOME THERAPEUTICS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-121887 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Human Microbiome Therapeutics Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET
7.1 GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA HUMAN MICROBIOME THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Bristol-Myers Squibb Co.
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Dow Inc.
16.3 ENTEROME SA
16.4 Ferring Pharmaceuticals AS
16.5 Johnson & Johnson
16.6 Kaleido Biosciences Inc.
16.7 PureTech Health Plc
16.8 Second Genome Therapeutics
16.9 Seres Therapeutics Inc.
16.10 Takeda Pharmaceutical Co. Ltd.
16.11 Vedanta Biosciences
16.12 Whole Biome
16.13 Naked Biome
16.14 Evelo Biosciences
16.15 LNC Therapeutics
16.16 Biotagenics
16.17 Oxidien Pharmaceuticals, LLC
16.18 BoobyBiome
16.19 4D Pharma PLC
16.20 UBiome
16.21 Carbiotix
16.22 E.I. du Pont de Nemours and Company
16.23 Finch Therapeutics
16.24 GNUbiotics Sciences
16.25 ClearB Therapeutics
16.26 GoodBelly
16.27 GoodGut
16.28 Synlogic
16.29 16S Technologies
16.30 5QBD-Biotech
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By Product TypeProbiotics
Prebiotics
Medical Foods
Prescription Drugs
By Therapeutic Area
Autoimmune Disorders
Dental Disorders
Digestive and Gastrointestinal Disorders
Dermatological Disorders
Infectious Disease
Metabolic Disorders
Oncology
Others
By Indication
Acne Vulgaris
Atopic Dermatitis
Clostridium difficile Infection
Colorectal Cancer
Diabetes
Inflammatory Bowel Disease (IBD)
Lactose Intolerance
Lung Cancer
Non-alcoholic steatohepatitis (NASH)
Obesity
Coeliac Disease
By Approach
Small Molecule Therapies
Single Strain Whole Bacteria
Microbial Consortia
Genetically Modified Single Strain Bacteria
Phage Cocktail
Microbial Ecosystems
Companies
Bristol-Myers Squibb Co.
Dow Inc.
ENTEROME SA
Ferring Pharmaceuticals AS
Johnson & Johnson
Kaleido Biosciences Inc.
PureTech Health Plc
Second Genome Therapeutics
Seres Therapeutics Inc.
Takeda Pharmaceutical Co. Ltd.
Vedanta Biosciences
Whole Biome
Naked Biome
Evelo Biosciences
LNC Therapeutics
Biotagenics
Oxidien Pharmaceuticals, LLC
BoobyBiome
4D Pharma PLC
UBiome
Carbiotix
E.I. du Pont de Nemours and Company
Finch Therapeutics
GNUbiotics Sciences
ClearB Therapeutics
GoodBelly
GoodGut
Synlogic
16S Technologies
5QBD-Biotech
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.